Skip to main content

Advertisement

SpringerLink
Log in

Reply: The BIM deletion polymorphism cannot account for intrinsic TKI resistance of Chinese individuals with chronic myeloid leukemia

  • Correspondence
  • Published:

From Nature Medicine

View current issue Submit your manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Chen, X., Liu, H., Xing, H., Sun, H. & Zhu, P. Nat. Med. 20, 1090 (2014).

    Article  CAS  Google Scholar 

  2. Ng, K.P. et al. Nat. Med. 18, 521–528 (2012).

    Article  CAS  Google Scholar 

  3. Lee, J.H. et al. J. Thorac. Oncol. doi:10.1097/JTO.0000000000000238 (23 July 2014).

  4. Zhao, M. et al. Cancer 120, 2299–2307 (2014).

    Article  CAS  Google Scholar 

  5. Isobe, K. et al. J. Thorac. Oncol. 9, 483–487 (2014).

    Article  CAS  Google Scholar 

  6. Lee, J.K. et al. Ann. Oncol. 24, 2080–2087 (2013).

    Article  CAS  Google Scholar 

  7. Shinohara, Y. et al. Haematologica 98, 1407–1413 (2013).

    Article  CAS  Google Scholar 

  8. Picard, S. et al. Blood 109, 3496–3499 (2007).

    Article  CAS  Google Scholar 

  9. Cortes, J., Goldman, J.M. & Hughes, T. J. Natl. Compr. Canc. Netw. 10 (suppl. 3), S1–S13 (2012).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer & Stem Cell Biology Signature Research Programme, Duke–National University of Singapore Graduate Medical School, Singapore

    S Tiong Ong, Charles T H Chuah & Tun Kiat Ko

  2. Department of Haematology, Singapore General Hospital, Singapore

    S Tiong Ong & Charles T H Chuah

  3. Department of Medical Oncology, National Cancer Centre, Singapore

    S Tiong Ong & Wan-Teck Lim

  4. Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA

    S Tiong Ong

  5. Cancer Therapeutics & Stratified Oncology, Genome Institute of Singapore, Singapore

    Axel M Hillmer

Authors
  1. S Tiong Ong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles T H Chuah
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tun Kiat Ko
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Axel M Hillmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wan-Teck Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Tiong Ong.

Ethics declarations

Competing interests

S.T.O., C.T.H.C. and A.M.H. hold a National University of Singapore, Singapore Health Services Pte. Ltd. and the Agency for Science, Technology and Research, Singapore patent (BRC/P/06094/01/PCT) for a method to detect resistance to cancer therapy and guide therapy to overcome resistance.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ong, S., Chuah, C., Ko, T. et al. Reply: The BIM deletion polymorphism cannot account for intrinsic TKI resistance of Chinese individuals with chronic myeloid leukemia. Nat Med 20, 1090–1091 (2014). https://doi.org/10.1038/nm.3652

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.3652

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation